Abstract: The present invention relates to the field of recombinant protein production in a host cell. More specifically the invention relates to the field of oral protein delivery. Specifically, the invention provides oral pharmaceutical formulations comprising the culture medium of a recombinant host secreting a recombinant protein. The resulting oral pharmaceutical formulations are useful for the treatment of gastro-intestinal and/or buccal disorders. Additionally, the oral pharmaceutical formulations are useful for prophylactic and vaccine purposes.

Abstract: The present invention relates to single-domain antibodies that specifically bind aminopeptidase N (APN), and more in particular to polypeptides, and nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the single-domain antibodies of the present invention are capable of targeting a moiety to a mucosal surface.

Abstract: This disclosure relates to an antibody that can protect against ETEC infection in a passive immunization set up. More specifically, it relates to a VHH grafted on an IgA scaffold and produced in plant seeds. When the seeds are given in food or feed, the subject is protected against ETEC infection.

Abstract: The present invention relates to the field of recombinant protein production in a host cell. More specifically the invention relates to the field of oral protein delivery. Specifically, the invention provides oral pharmaceutical formulations comprising the culture medium of a recombinant host secreting a recombinant protein. The resulting oral pharmaceutical formulations are useful for the treatment of gastro-intestinal and/or buccal disorders. Additionally, the oral pharmaceutical formulations are useful for prophylactic and vaccine purposes.

Abstract: The present invention relates to T-DNA vectors and methods for obtaining transgenic eukaryotes using said vectors. The transgenic eukaryotes are characterized in that they contain the T-DNA but not the illegitimately transferred vector backbone sequence. This is achieved by modifying the T-DNA borders such that they are more efficiently nicked or such that they allow elimination of illegitimately transferred vector backbone sequences by means of recombination.

Abstract: The present invention relates to T-DNA vectors and methods for obtaining transgenic eukaryotes using said vectors. The transgenic eukaryotes are characterized in that they contain the T-DNA but not the illegitimately transferred vector backbone sequence. This is achieved by modifying the T-DNA borders such that they are more efficiently nicked or such that they allow elimination of illegitimately transferred vector backbone sequences by means of recombination.

Abstract: The present invention relates to T-DNA vectors and methods for obtaining transgenic eukaryotes using said vectors. The transgenic eukaryotes are characterized in that they contain the T-DNA but not the illegitimately transferred vector backbone sequence. This is achieved by modifying the T-DNA borders such that they are more efficiently nicked or such that they allow elimination of illegitimately transferred vector backbone sequences by means of recombination.

Abstract: The invention relates to a method for efficient RNA silencing of target genes in eucaryotic cells, particularly plant cells. Consequently, the method can be used to reduce the phenotypic expression of an endogenous gene in a plant cell. Furthermore, the method can be applied in a high throughput screening for mutant phenotypes as a result of RNA silencing of any endogene.

Abstract: The present invention relates to heterologous gene expression in plants. More specifically, the invention relates to high expression of heterologous proteins in seeds, by incorporating the gene between seed specific sequences. Preferably, the heterologous protein is a single-chain antibody variable fragment (scFv).

Abstract: The present invention relates to T-DNA vectors and methods for obtaining transgenic eukaryotes using said vectors. The transgenic eukaryotes are characterized in that they contain the T-DNA but not the illegitimately transferred vector backbone sequence. This is achieved by modifying the T-DNA borders such that they are more efficiently nicked or such that they allow elimination of illegitimately transferred vector backbone sequences by means of recombination.